Perioperative Safety and Early Patient and Device Outcomes Among Subcutaneous Versus Transvenous Implantable Cardioverter Defibrillator Implantations : A Randomized, Multicenter Trial
Jeff S Healey,Andrew D Krahn,Jamil Bashir,Guy Amit,François Philippon,William F McIntyre,Bernice Tsang,Jacqueline Joza,Derek V Exner,David H Birnie,Mouhannad Sadek,Darryl P Leong,Markus Sikkel,Victoria Korley,John L Sapp,Jean-Francois Roux,Shun Fu Lee,Gloria Wong,Angie Djuric,Danna Spears,Sandra Carroll,Eugene Crystal,Tom Hruczkowski,Stuart J Connolly,Blandine Mondesert,ATLAS Investigators,Tim Stivland,Mark Mosley,Peter Aitkins,John Sapp,Jason D Roberts,Amir Janmohamed,Francois Philippon,Andrew Epstein,John Cairns,Kevin Thorpe,Naif Saad,Harry Klimis,Felipe Cirne,Osama Eltebi,Aditya Khetan,Tais Araujo,Hisham Dokainish,Chris Lane,Marc Dubuc,Vidal Essebag,Darryl Leong,Benoît Plourde,Bernard Thibault,Christian Steinberg,Zachary Laksman,Kim Simek,Roberta Napoleoni,Brook Snider,Kailey Howell,Lauren Christmas,Svetlana Stoyanova-Brennecke,Kiran Qamar,Francois Lemarbre,Julie Lefebvre,Faye McCarthy,Ambreen Syeda,Nancy Page,Marina Sanchez,Marie-Christine Cote,Annette Nath,Pei Ying,Caitlin Patterson,Elisa Ramser,Nadia Vachon,Rebecca Cairns,Marta Gadacz,Melissa Braga Gomes
DOI: https://doi.org/10.7326/M22-1566
Abstract:Background: Implantable cardioverter defibrillators (ICDs) improve survival in patients at risk for cardiac arrest, but are associated with intravascular lead-related complications. The subcutaneous ICD (S-ICD), with no intravascular components, was developed to minimize lead-related complications. Objective: To assess key ICD performance measures related to delivery of ICD therapy, including inappropriate ICD shocks (delivered in absence of life-threatening arrhythmia) and failed ICD shocks (which did not terminate ventricular arrhythmia). Design: Randomized, multicenter trial. (ClinicalTrials.gov: NCT02881255). Setting: The ATLAS trial. Patients: 544 eligible patients (141 female) with a primary or secondary prevention indication for an ICD who were younger than age 60 years, had a cardiogenetic phenotype, or had prespecified risk factors for lead complications were electrocardiographically screened and 503 randomly assigned to S-ICD (251 patients) or transvenous ICD (TV-ICD) (252 patients). Mean follow-up was 2.5 years (SD, 1.1). Mean age was 49.0 years (SD, 11.5). Measurements: The primary outcome was perioperative major lead-related complications. Results: There was a statistically significant reduction in perioperative, lead-related complications, which occurred in 1 patient (0.4%) with an S-ICD and in 12 patients (4.8%) with TV-ICD (-4.4%; 95% CI, -6.9 to -1.9; P = 0.001). There was a trend for more inappropriate shocks with the S-ICD (hazard ratio [HR], 2.37; 95% CI, 0.98 to 5.77), but no increase in failed appropriate ICD shocks (HR, 0.61 (0.15 to 2.57). Patients in the S-ICD group had more ICD site pain, measured on a 10-point numeric rating scale, on the day of implant (4.2 ± 2.8 vs. 2.9 ± 2.2; P < 0.001) and 1 month later (1.3 ± 1.8 vs. 0.9 ± 1.5; P = 0.035). Limitation: At present, the ATLAS trial is underpowered to detect differences in clinical shock outcomes; however, extended follow-up is ongoing. Conclusion: The S-ICD reduces perioperative, lead-related complications without significantly compromising the effectiveness of ICD shocks, but with more early postoperative pain and a trend for more inappropriate shocks. Primary funding source: Boston Scientific.